Pricing Log in Create free account
Saturday 17 October 2026 Export COLL’s income statement to Excel — free account

Collegium Pharmaceutical, Inc.

COLL Healthcare Drug Manufacturers Specialty & Generic

Collegium Pharmaceutical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $780.6 million, up 23.6% from fiscal 2024. In the quarter to June 2026, revenue grew 6.32%, EPS fell 221.1%, free cash flow fell 2.14% and total debt rose 32.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

23.19 0.01 +0.04%
Market cap
$754.6M
P/E
15.2×
Fwd P/E
12.5×
Dividend yield
—
F-score
7/9
Altman Z
1.58
Beneish M
−3.32
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 7.25
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 2 2 — — 3 — 4 — — — — —
Insider Ownership 1.57%

Capital & Financial Ratios $m

Market Cap 754.64
Revenue 808.21
Net Income 47.92
Free Cash Flow 328.28
Net Debt 942.24
Current Ratio 1.03
Debt/Equity 3.50 (above 2: weak)
P/E ratio 15.16
Fwd P/E 12.50
P/S ratio 0.93
P/B ratio 2.41
Past 5Y EPS Growth 17.88% (at or above 15%: strong)
This Y EPS Growth 0.52%
Next Y EPS Growth (2.68%) (below 0%: weak)
Next Y revenue growth 6.85%
Next 5Y EPS Growth 1.25%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.1×, against a ten-year median of 2.6×; over the ten years it ranged from 0.8× in 2019 to 34.9× in 2017.
P/E against its own 10 years 46.01%
10-year low 10-year high
P/S against its own 10 years 1.16%
10-year low 10-year high
P/B against its own 10 years 2.69%
10-year low 10-year high
EV/Sales against its own 10 years 18.49%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 311 188 407 149
Receivables 180 229 211 285
Inventory 32 36 41 113
Other — — — —
538 482 691 608
2023 2024 2025 Q'26
Payables 9 4 11 9
ST’ Debt 183 65 29 55
Other — 29 18 45
458 510 440 590

Compound Annual Growth %

10y 5y 3y
Sales — 20.28% 18.94%
Cash Flow 0.00% 28.51% 38.40%
Earnings 0.00% 18.64% 0.00%
Book Value 13.49% 10.15% 15.69%

Revenue $m

Mar Jun Sep Dec Year
’26 194 200 — — —
’25 178 188 209 205 781
’24 145 145 159 182 631
’23 145 136 137 150 567
’22 84 124 127 130 464
’21 88 83 79 27 277
’20 77 78 79 76 310
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 57 71 — — —
’25 55 72 78 123 329
’24 62 67 (9) 85 205
’23 28 100 74 73 275
’22 (25) 40 43 66 124
’21 21 30 17 36 104
’20 (7) 44 34 23 94
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 57 71 — — —
’25 55 72 78 122 328
’24 61 67 (9) 84 203
’23 27 100 74 73 274
’22 (25) 40 43 65 123
’21 20 29 17 36 102
’20 (374) 42 32 21 (280)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.40 (0.46) — — —
’25 0.07 0.34 0.84 0.46 1.73
’24 0.71 0.52 0.27 0.36 1.86
’23 (0.51) 0.34 0.53 0.82 1.29
’22 (0.39) (0.15) 0.01 (0.21) (0.74)
’21 0.41 1.79 0.22 (0.73) 1.86
’20 0.01 0.23 0.32 0.20 0.76
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 8.24 7.37 13.70 10.01 13.00 17.22 14.04 20.83 28.47 23.23

Analyst estimates 2026–2028

Powerpack
High 28.47 20.92 29.90 22.28 25.59 26.91 24.36 31.12 42.29 50.79
People
People Employees 234 250 266 255 234 152 207 197 357 423
Revenue/emp, $m 0.01 0.11 1.05 1.16 1.32 1.82 2.24 2.88 1.77 1.85
Income, $m
Income, $m Revenue 2 28 280 297 310 277 464 567 631 781
Gross margin, % 87.55 90.89 40.92 34.73 58.01 54.40 45.15 57.55 59.76 59.35
EBT (94) (75) (39) (23) 28 (3) (29) 76 99 93
EBT margin, % (5,504.15) (262.91) (13.95) (7.66) 8.90 (1.22) (6.22) 13.36 15.61 11.87
Net income (94) (75) (39) (23) 27 72 (25) 48 69 63
Depreciation 1 1 111 15 62 69 139 148 167 225
Per share, $
Per share, $ Revenue 0.07 0.94 8.51 8.87 9.01 7.92 13.71 16.80 19.57 24.62
Earnings (3.88) (2.47) (1.19) (0.68) 0.78 2.05 (0.74) 1.43 2.14 1.98
Cash flow (3.09) (2.21) 5.14 0.83 2.73 2.96 3.67 8.14 6.35 10.39
Capex (0.02) (0.03) (0.74) (0.19) (10.86) (0.06) (0.05) (0.01) (0.05) (0.05)
Free cash flow (3.11) (2.25) 4.40 0.64 (8.13) 2.91 3.62 8.13 6.30 10.33
Book value 5.56 3.44 2.78 2.61 5.41 5.81 5.76 5.79 7.09 9.51
Shares, m 24 30 33 33 34 35 34 34 32 32
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 26.01 9.29 0.00 21.24 13.39 23.15
P/S 0.00 19.87 2.02 2.32 2.22 2.36 1.72 1.86 1.46 1.88
P/B 2.82 5.44 6.18 7.87 3.70 3.22 4.09 5.39 4.04 4.87
EV/Sales 0.00 15.77 1.54 1.79 2.49 2.59 2.86 2.49 2.52 2.40
EV/FCF (3.06) (6.60) 3.02 (16,561.38) (2.76) (2.69) (5.39) (15.01) (9.64) (46.03)
Cash, $m
Cash, $m Operating cash flow (75) (67) 169 28 94 104 124 275 205 329
Capex 0 (1) (24) (6) (374) (2) (2) 0 (2) (2)
Free cash flow (76) (68) 145 21 (280) 102 123 274 203 328
Balance, $m
Balance, $m Working capital 133 102 48 54 38 36 (14) 80 (27) 251
Total debt 4 1 12 12 257 250 701 667 852 809
Net debt (149) (117) (135) (159) 83 64 527 357 665 403
Shareholders’ equity 135 104 92 87 186 203 195 195 229 302
Returns, %
Returns, % ROA (72.52) (50.32) (18.33) (7.61) 5.63 10.71 (2.68) 4.16 4.93 3.79
ROIC 0.00 0.00 0.00 0.00 13.06 4.13 2.88 18.90 11.88 15.94
ROE (85.62) (62.65) (39.99) (25.39) 19.57 36.77 (12.57) 24.68 32.62 23.70
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Collegium Pharmaceutical, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CRON Cronos Group Inc. $1.2B 16.1× 32.2× +58.44% (above 0%: growing) n/m +2,279.22% (above 0%: growing) 53.67% 13.97% Compare
AMPH Amphastar Pharmaceuticals, Inc. $1.1B 14.9× 14.7× +5.44% (above 0%: growing) +4.55% (above 0%: growing) +87.61% (above 0%: growing) 50.83% 21.60% Compare
HROW Harrow, Inc. $1.1B — (loss-making) 134× +10.85% (above 0%: growing) n/m −838.78% (below 0%: shrinking) 71.27% (15.58%) Compare
COLL Collegium Pharmaceutical, Inc. $754.6M 15.2× 12.5× +6.32% (above 0%: growing) n/m −2.14% (below 0%: shrinking) 55.18% 1.85%
IRWD Ironwood Pharmaceuticals, Inc. $623.0M 4.4× 2.8× +32.62% (above 0%: growing) +106.67% (above 0%: growing) +486.70% (above 0%: growing) 100.00% 70.16% Compare
AQST Aquestive Therapeutics, Inc. $509.6M — (loss-making) — (loss-making) +38.15% (above 0%: growing) n/m −20.35% (below 0%: shrinking) 70.93% (59.51%) Compare
EVO Evotec AG $504.4M — (loss-making) — (loss-making) −12.98% (below 0%: shrinking) n/m −9,727.20% (below 0%: shrinking) (1.00%) (77.50%) Compare
EOLS Evolus, Inc. $500.0M — (loss-making) — (loss-making) +21.18% (above 0%: growing) n/m +84.90% (above 0%: growing) 68.00% (5.40%) Compare
TLRY Tilray Brands, Inc. $474.4M — (loss-making) — (loss-making) +22.74% (above 0%: growing) n/m −36.60% (below 0%: shrinking) 30.14% (9.35%) Compare
Median of peers $566.3M 14.9× 23.5× +21.96% — +32.28% 60.84% (7.37%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Collegium Pharmaceutical, Inc. (COLL) key facts

  • Strength: Collegium Pharmaceutical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $780.6 million, up 23.6% from fiscal 2024.
  • Collegium Pharmaceutical, Inc. (COLL) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, COLL traded at $23.19, a market capitalization of $754.6 million.
  • Return on equity was 23.7% and debt-to-equity 3.50.
  • Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 1.58 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Collegium Pharmaceutical, Inc. (COLL) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/COLL · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com